MedTrace Logo

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

NCT06004960 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-08-22

No results posted yet for this study

Summary

The primary objective of this study is to perform mass balance following a single oral dose of \[14C\]CCX168 in healthy adult male participants.

Conditions

  • Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

DRUG

[14C]CCX168

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-20
Primary Completion
2014-12-05
Completion
2014-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06004960 on ClinicalTrials.gov